Field of application: The invention relates to combinatorial chemistry, pharmacy and cosmetology, allows to synthesize new combinatorial libraries of derivatives of antibiotics for use in pharmacy, cosmetology and pharmacy.

Technical result: modified combinatorial derivatives of antibiotics with antimicrobial and antifungal activity against multiresistant and pan drug resistance strains of microorganisms and fungi. Means have a wide spectrum of action, and the supramolecular and combinatorial structure of their tens and hundreds of derivatives eliminates the resistance of microorganisms.

Provided are a ligand-bearing substrate which has a surface at least partially coated with a polymer (P3) containing structural units represented by the formulae (1a) and (1b) (in the formulae, R.sup.1, R.sup.2, X, Y, L, Q.sup.1, Q.sup.2, Q.sup.3, m1, m2 and n are as described in the claims and description); a raw material for such a substrate; and a method for producing such substrates.

The present disclosure generally relates to a process for manufacturing liposomes containing polymyxin and quinolone as a treatment for bacterial infections. In particular, the present invention utilizes an anionic lipid as an essential component of a liposome for efficient encapsulation of polymyxin and quinolone, which affords a stable more efficient pharmaceutical composition for the treatment of a bacterial infection, especially infections of the lungs. Pharmaceutical compositions and methods of treatment are within the scope of this invention.

##STR00001##

The present invention relates to identification of inhibitors or antagonists of aminoarabinase glycosyltransferase (ArnT) and their use in compositions, methods of treatment or prevention of drug resistant gram negative infections, or inhibiting the growth of gram negative bacterial infections resistant to polymyxin-class antibiotics. In certain aspects, the inhibitors or antagonists can be administered in combination with one or more antibacterial agents.

The present invention relates to identification of inhibitors or antagonists of aminoarabinase glycosyltransferase (ArnT) and their use in compositions, methods of treatment or prevention of drug resistant gram negative infections, or inhibiting the growth of gram negative bacterial infections resistant to polymyxin-class antibiotics. In certain aspects, the inhibitors or antagonists can be administered in combination with one or more antibacterial agents.

Field of application: The invention relates to medicine and pharmacy and allows to obtain new pharmaceutical compositions based on polymyxin for the treatment of severe infectious diseases, but not possessing nephrotoxic properties in therapeutic doses.

Technical result: New combined dosage forms based on the antibiotic polymyxin with low nephrotoxicity and high activity.

A polymyxin B component or salts thereof, and a preparation and application thereof. The polymyxin B component includes six ,-diaminobutyric acids respectively at positions 1, 3-5 and 8-9, two threonine residues at positions 2 and 10, a phenylalanine residue at position 6 and a leucine residue at position 7 linked in sequence. The threonine residue at position 10 is linked to the ,-diaminobutyric acid at position 4 by an amido bond, and the ,-diaminobutyric acid at position 1 is linked to 6-methyloctyl-2-enoyl.

A polymyxin B component or salts thereof, and a preparation and application thereof. The polymyxin B component includes six ,-diaminobutyric acids respectively at positions 1, 3-5 and 8-9, two threonine residues at positions 2 and 10, a phenylalanine residue at position 6 and a leucine residue at position 7 linked in sequence. The threonine residue at position 10 is linked to the ,-diaminobutyric acid at position 4 by an amido bond, and the ,-diaminobutyric acid at position 1 is linked to 6-methyloctyl-2-enoyl.

The present invention relates to antimicrobial compounds and their uses, and in particular to peptide antibiotics which may be used in the treatment of bacterial infections such as Gram-negative bacterial infections, particularly those caused by multidrug-resistant (MDR) pathogens.

The present invention relates to antimicrobial compounds and their uses, and in particular to peptide antibiotics which may be used in the treatment of bacterial infections such as Gram-negative bacterial infections, particularly those caused by multidrug-resistant (MDR) pathogens.